What is the diagnostic approach and initial management for a suspected thrombotic microangiopathy (TMA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnostic Approach for Thrombotic Microangiopathy (TMA)

When you encounter anemia plus thrombocytopenia in the emergency department, immediately order haptoglobin, indirect bilirubin, and LDH levels to evaluate for TMA 1.

Confirm the Syndromic Diagnosis

TMA requires the presence of three core features 1:

  • Thrombocytopenia: Platelets <150,000/mm³ or a 25% reduction from baseline
  • Microangiopathic hemolytic anemia:
    • Negative direct Coombs test (non-immune hemolysis)
    • Elevated LDH
    • Reduced haptoglobin
    • Schistocytes on peripheral blood smear (>1% supports diagnosis, but absence does not exclude TMA due to low test sensitivity)
  • Renal involvement: Hematuria and/or proteinuria and/or elevated creatinine

Critical pitfall: Do not wait for schistocytes to make the diagnosis—their absence should not delay TMA diagnosis or treatment 1.

Urgent Differential Diagnosis Testing

Before initiating any treatment, draw blood for ADAMTS13 activity and send stool for VTEC (verocytotoxin-producing E. coli) 1. These tests distinguish between:

  • TTP (Thrombotic Thrombocytopenic Purpura): ADAMTS13 activity <10 IU/dL
  • STEC-HUS: Positive stool VTEC (typically appears 4-5 days after diarrhea onset)
  • Atypical HUS (aHUS): Negative for both above

ADAMTS13 testing must be conducted urgently when TMA is suspected 1.

Initial Management Algorithm

Step 1: Immediate Actions

  • Admit to ICU for monitoring
  • Draw pre-treatment samples for ADAMTS13 and complement studies
  • Check stool for VTEC if any diarrheal history
  • Obtain first-level labs: CBC, comprehensive metabolic panel, LDH, haptoglobin, indirect bilirubin, direct Coombs test, urinalysis with microscopy

Step 2: Empiric Treatment Decision

If ADAMTS13 results are not immediately available and the patient is critically ill, initiate plasma exchange within 4-8 hours 2. This treats TTP (the most immediately life-threatening form) while awaiting definitive diagnosis.

Step 3: Etiologic Classification

Once ADAMTS13 and VTEC results return:

  • ADAMTS13 <10%: Diagnose TTP, continue plasma exchange
  • Positive VTEC: Diagnose STEC-HUS, provide supportive care (plasma exchange generally not indicated)
  • Both negative: Consider aHUS or secondary TMA

Step 4: Further Workup for aHUS/Secondary TMA

First-level tests 1:

  • Complete blood count with differential
  • Comprehensive metabolic panel
  • Coagulation studies
  • Blood cultures
  • Pregnancy test (if applicable)
  • HIV, hepatitis serologies

Second-level tests 1:

  • Complement studies (C3, C4, CH50, factor H, factor I)
  • Genetic testing for complement pathway mutations
  • ANA and autoimmune panel
  • Drug exposure history (calcineurin inhibitors, quinine, chemotherapy agents)

Special Populations

Children

  • If <1 year old: Consider mutations in complement-unrelated genes (DGKE, WT1) and methylmalonic acidemia with homocystinuria (MMACHC) 1
  • With diarrhea: If diarrhea and HUS appear simultaneously or within 1-2 days, suspect aHUS rather than STEC-HUS (which typically has 4-5 day lag) 1

Post-Transplant Patients

Do not exclude TMA diagnosis based on absence of marked thrombocytopenia or significant anemia in transplant recipients—TMA can present with isolated renal findings in this population 1.

Pregnancy-Associated TMA

  • Measure sFlt1/PlGF ratio to distinguish from pre-eclampsia
  • Low sFlt1/PlGF ratio (<38) excludes pre-eclampsia and supports complement-mediated TMA diagnosis 3

Neurological Involvement

If neurological symptoms develop (seizures, encephalopathy, motor weakness, vision changes):

  • Obtain neurology consultation
  • Perform EEG and brain MRI with FLAIR and T2-weighted sequences
  • Look for bilateral symmetric basal ganglia hyperintensities (suggestive of TMA) 1

Neurological involvement occurs in only 10-20% of aHUS cases but requires urgent evaluation 1.

Treatment Initiation for Complement-Mediated TMA

If aHUS is confirmed (negative ADAMTS13, negative VTEC, with or without complement mutations), initiate C5 inhibitor therapy immediately 1. Before starting:

  • Vaccinate against meningococcus (quadrivalent A, C, W, Y) if not already done
  • Note: Patients of Chinese/Japanese descent may have C5 polymorphisms (c.2654 G→A, c.2653 C→T) causing resistance to anti-C5 monoclonal antibodies 1

References

3
Research

Thrombotic Microangiopathy During Pregnancy: Role of Soluble Fms-like Tyrosine Kinase-1-Placental Growth Factor Ratios.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2026

Related Questions

What are the recommended diagnostic evaluations and initial treatment strategies for thrombotic microangiopathy in children?
What is the treatment approach for thrombotic microangiopathy (TMA), including conditions like thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS)?
How to manage Thrombotic Microangiopathy (TMA) in patients with mechanical heart valves?
What is the appropriate treatment for Thrombotic Microangiopathy (TMA)?
In a 70‑year‑old woman with severe rhabdomyolysis, acute kidney injury, heavy proteinuria, hematuria, thrombocytopenia and anemia unresponsive to intravenous fluids and hemodialysis, and negative ANCA, SPEP and urine protein electrophoresis, what is the next appropriate management?
What does a PHQ‑9 score of 17 indicate and how should major depressive disorder be diagnosed based on this score?
After administering Xylocard (lidocaine) and coraderone (corticosteroid) for recurrent ventricular tachycardia, what is the appropriate next step in management?
In a patient with activity‑related fluctuating generalized weakness, intermittent ptosis, fatigable dysphonia, dysphagia, chewing difficulty, head‑droop and choking when supine, but with normal electromyography and negative acetylcholine‑receptor antibodies, could Myasthenia gravis be a differential or co‑existing disorder, and how can it be definitively ruled out?
What is the appropriate famotidine (Pepcid) dose for a child experiencing an allergic reaction?
Is sotalol appropriate for acute management of recurrent ventricular tachycardia after lidocaine and amiodarone have failed?
What is the pharmacologic management of hemoptysis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question